期刊文献+

滋水涵木法治疗慢性乙型肝炎临床疗效的系统评价研究 被引量:5

Evaluating clinical efficacy of treating chronic hepatitis B by the Ziahui Hanmu therapy
下载PDF
导出
摘要 目的:探讨滋水涵木法治疗慢性乙型肝炎的临床疗效。方法:本次医学研究选择我院于2013年1月-2014年1月之间收治的100例慢性乙型肝炎患者为观察对象,随机将其分为对照组和实验组,对照组接受常规护肝治疗,实验组接受滋水涵木法治疗,对比分析两组患者的临床疗效。结果:实验组患者的临床治疗总有效率和乙肝病毒标志物指标检查结果均明显优于对照组(P<0.05)。结论:慢性乙型肝炎患者接受滋水涵木法治疗,具有较为理想的临床疗效,因而推广和应用价值较高。 Objective: To explore clinical efficacy of the Zishui Hanmu therapy on chronic hepatitis B. Methods: From January 2013 to January 2014, 100 cases of chronic hepatitis B were randomly divided into the control group and treatment group. The control group received conventional Liver treatment, and the other group received the Zishui Hanmu therapy, while comparing clinical efficacy. Results: The total efficiency and test results of HBVM index in the treatment group was obviously better (P<0.05). Conclusion: Treating chronic hepatitis B by the Zishui Hanmu therapy could obtain ideal clinical efficacy, and be worthy of promotion.
作者 徐雪芹
机构地区 邳州市中医院
出处 《中医临床研究》 2015年第16期87-88,共2页 Clinical Journal Of Chinese Medicine
关键词 滋水涵木法 慢性乙型肝炎 临床疗效 系统评价 The Zishui Hanmu therapy Chronic hepatitis B Clinical efficacy Evaluation system
  • 相关文献

参考文献4

二级参考文献26

  • 1赵文丽.抗乙型肝炎病毒药替比夫定[J].国外医学(药学分册),2004,31(4):231-233. 被引量:17
  • 2中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华流行病学杂志,2006,27(1):79-88. 被引量:391
  • 32006年~2010年全国乙型病毒性肝炎防治规划[J].中国实用乡村医生杂志,2006,13(8):1-4. 被引量:51
  • 4许洁,陆志檬.替比夫定治疗慢性乙型肝炎的进展[J].中华肝脏病杂志,2006,14(12):958-959. 被引量:37
  • 5世界卫生组织.EB/OL.2009-09.http://www.who.int/mediacentre/factsheets/fs204/zh/index.html.
  • 6Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
  • 7Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, LloydD, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536.
  • 8Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in pa- tients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
  • 9Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447-454.
  • 10Safadi R, Xie Q, Chen Y, Yin YK, Wei L, Hwang SG, Zuckerman E, Tia JD, Harb G, Brown NA. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J Hepatol 2007; 46:$196.

共引文献20

同被引文献70

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部